Newcastle Clinical Trials Unit



A single-centre, experimental medicine study investigating the route of delivery and efficacy of autologous tolerogenic dendritic cell (tolDC) therapy for Rheumatoid Arthritis.

Study stage: Set-up
Sponsor: The Newcastle upon Tyne Hospitals NHS Foundation Trust
Funder: Versus Arthritis
Therapeutic area: Musculoskeletal
Type of study: ATIMP

Aim: Demonstrate safety of tolDC administration for intra-articular, intra-dermal and intra-nodal routes.
Identify optimal route of administration to ensure tolDC reaches secondary lymphoid tissue.

Population: Adults
Clinical Phase: IIa
Design: Randomised Control Trial (RCT)
Setting: Secondary Care